Skip to main content

patientMpower’s Specialist Respiratory Remote Monitoring Platform Approved by NHSX

By November 28, 2020August 31st, 2021No Comments

patientMpower, a provider of specialist remote monitoring platforms for respiratory conditions, have been listed as an approved supplier of remote monitoring services by NHSX.

We are delighted to announce that patientMpower’s specialist remote monitoring platform has been announced as an approved Spark Dynamic Purchase System (DPS) supplier by NHSX.



NHSX, the digital transformation programme within the NHS, aims to support organisations with the procurement of remote monitoring solutions. The Spark DPS offers the NHS and social care organisations a fast, easy and secure way to access the technologies and services needed to provide more care to people, closer to, or within their own home.

patientMpower have proven solutions, tested at scale which can help NHS organisations implement remote monitoring solutions.

COVID-19 Remote Monitoring

In February 2020, patientMpower adapted our existing respiratory remote monitoring solution for COVID-19. Patients prescribed the solution use an app which integrates with a bluetooth pulse oximeter which measures patients’ oxygen saturation and heart rate.

Patients can also record their level of breathlessness, their temperature and other symptoms. All information captured by patients in the app is immediately available for health service staff to view in a secure patient data portal, or via Patients Know Best shared care record system in certain NHS trusts. Healthcare staff can then make informed decisions about the ongoing care needs of patients being monitored, and will be alerted, for example when the oxygen saturation drops below a defined value (e.g. 94%). Oxygen saturation is known to be a key early indicator of coronavirus severity or silent hypoxia.

Our COVID-19 virtual ward solution was deployed by the national healthcare system in Ireland, where it has been attributed in helping hospitals manage capacity and resources during the pandemic, and has since been used by large US healthcare organisations such as Mount Sinai, New York.

Respiratory Disease Monitoring

patientMpower’s solutions are deployed in a range of long term respiratory conditions such as COPD, interstitial lung disease (ILD) such as Pulmonary Fibrosis, Cystic Fibrosis, and lung transplant. Our solutions use integrated spirometry to record Forced Vital Capacity (FVC) and Forced Expiratory Volume (FEV1) and other lung function measures.

The patientMpower solution is a Class I software medical device, and all devices which connect to the platform (oximeters, spirometers) are also medical devices.

What does NHSX approval mean?

Approval by NHSX provides patientMpower with a significant advantages in accessing the UK healthcare system. This recognition means NHS healthcare trusts can be reassured that the platform has undergone review by NHSX and has met the required demands, reducing much of the burden placed on individual centres in assessing the clinical and data protection issues of these new technologies.

How can I find out more?

To discuss how to design and deliver new care pathways to ensure continuity of care for your patients in the COVID-19 pandemic and beyond, please contact us by emailing, calling us at +44 20 3322 4121.